[{"orgOrder":0,"company":"Juvena Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Protein","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery Platform","graph3":"Juvena Therapeutics","amount2":0.65000000000000002,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.65000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Juvena Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Juvena Therapeutics \/ Eli Lilly"}]

Find Nutrition and Weight Loss Clinical Drug Pipeline Developments & Deals by Juvena Therapeutics

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          ACS GCI
                          Not Confirmed
                          ACS GCI
                          Not Confirmed

                          Details : The collaboration with Lilly will help to identify muscle targeting drug candidates from Juvena’s library of human stem-cell secreted proteins for improved body composition & muscle health.

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Undisclosed

                          June 11, 2025

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Discovery Platform

                          Sponsor : Eli Lilly

                          Deal Size : $650.0 million

                          Deal Type : Collaboration

                          blank